Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study

Condition:   Non-small Cell Lung Cancer Interventions:   Biological: pembrolizumab;   Drug: carboplatin;   Drug: paclitaxel;   Drug: pemetrexed Sponsor:   Merck Sharp & Dohme Corp. Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials